AORT Artivion, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AORT matters now
Artivion, Inc. (AORT) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.09 with -0.08% on the session and $1.17B in market capitalization; recent performance reads 1-month -6.78% and YTD -53.54%.
The latest financial table shown here is Q1 2026, with revenue of $116.3M, net income of $1.4M, and EPS of $0.03. Investors can compare that operating picture with valuation signals such as P/E 184.47 and FCF yield 1.2%.
The latest indexable market news headline is "Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.50; recent insider activity includes GREEN ANDREW M filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
184.47
PEG
1.07
P/B
2.26
P/S
2.24
EV/EBITDA
18.92
DCF Value
$-0.32
FCF Yield
1.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.9%
Operating Margin
7.8%
Net Margin
2.5%
ROE
2.7%
ROA
1.3%
ROIC
3.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $116.3M | $1.4M | $0.03 |
| Q4 2025 | $116.0M | $2.4M | $0.05 |
| FY 2025 | $441.3M | $9.8M | $0.21 |
| Q3 2025 | $113.4M | $6.5M | $0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$40.50
Target (Median)
$40.50
Target Range
$36.00 - $45.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.26
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.